Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Regulator Wipes Smirk Off Smiles Powder's Fast-Whitening Claims

Executive Summary

Smile Powder UK advised to modify website claims suggesting Smirk Tooth Powder could provide whitening benefits "moments" after use, UK Advertising Standards Authority says.

You may also be interested in...



Health And Wellness Market News: FTC Settlement, FDA Alert, UK Ad Reviews

FTC settles with operators of a bogus cognitive supplement sales ring for $26.2m; FDA warns on unapproved at-home head injury tests; and UK advertising regulator says HiSmile claims fail, P&G Always Discreet claims pass.

HBW Executive Decisions: Perrigo Americas, Nutraceutical International Helm Changes, ABC Farnsworth Award, More

Myos Rens hires Eric LeGrand as special advisor for sports nutrition; Perrigo Consumer Americas chief Jeff Needham will be succeeded by Rich Sorota; Nutraceutical International appoints Monty Sharma to replace Chad Clawson at the helm; American Botanical Council’s Farnsworth Award goes to Rachel Mata; and Herbalife’s John Agwunobi will be chairman as well as CEO.

Bausch Expects US Approval In 2020 Of Preservative-Free OTC Ketotifen Eye Drop

Bausch says it expects US FDA to approve its ANDA for the first preservative-free OTC eye drop for ocular itching associated with allergic conjunctivitis in the second half of 2020. The firm reports its Lumify redness relief drops generated sales of $63m for 2019.

Topics

UsernamePublicRestriction

Register

RS148897

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel